Skip to main content

Table 3 MBD2 Haplotypes, menopausal status and breast cancer risk in Caucasians

From: Genotypes and haplotypes of the methyl-CpG-binding domain 2 modify breast cancer risk dependent upon menopausal status

MBD2 Haplotypes Frequency in cases Frequency in controls Crude OR (95% CI) ORa (95% CI)
All women
GC 69.22% 66.90% Reference Reference
GG 4.81% 5.56% 0.84 (0.53–1.31) 0.82 (0.52–1.29)
AC 11.17% 11.70% 0.92 (0.68–1.26) 0.92 (0.67–1.25)
AG 14.81% 15.84% 0.90 (0.69–1.19) 0.90 (0.68–1.19)
Premenopausal women
GC 77.65% 63.29% Reference Reference
GG 5.29% 5.59% 0.77 (0.33–1.80) 0.77 (0.33–1.81)
AC 6.47% 12.59% 0.42 (0.21–0.85) 0.40 (0.20–0.83)
AG 10.59% 18.53% 0.47 (0.26–0.83) 0.47 (0.26–0.84)
Postmenopausal women
GC 66.83% 68.75% Reference Reference
GG 4.67% 5.54% 0.87 (0.51–1.47) 0.84 (0.49–1.44)
AC 12.50% 11.25% 1.14 (0.80–1.64) 1.14 (0.79–1.65)
AG 16.00% 14.46% 1.14 (0.82–1.58) 1.13 (0.81–1.57)
  1. Values are expressed as n (%). aAdjusted for age (as a continuous variable), body mass index (<25 kg/m2, 25–29.99 kg/m2, >29.99 kg/m2), family history of breast cancer in first-degree relatives, menopausal status, family income (tertiles based on distribution of controls), lifetime months of breast feeding (never, 1–5, 6–15, ≥15 months) and study site. CI, confidence interval; OR, odds ratio.